Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902928 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
A Phase 2 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 1,992
- Enrollment target
NCT00902928: Completed Phase 2 study, sponsored by Astellas Pharma Europe B.V..
NCT00902928 is a Phase 2 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 1,992 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1398% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00902928, a Phase 2 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,992 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.
Interventions
- DRUG enoxaparin
- DRUG YM150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,992 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT00902928 record still lists
NCT00902928 is an interventional study that assigns participants to a tested intervention. Its 1,992 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1398% higher).
The record links to 0 conditions, and to 2 interventions - of which enoxaparin is the first listed.
NCT00902928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00902928 about?
NCT00902928 is a clinical study titled "A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery". The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.
What is the current status of trial NCT00902928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,992 participants. The study started on 2009-04. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00902928?
The interventions under investigation include: enoxaparin (DRUG), YM150 (DRUG).
Who is sponsoring clinical trial NCT00902928?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00902928's enrollment target sits among peer trials
1,992 9th of 2000 higher than 1,992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia